Cohen & Steers Global Income Builder Inc

9.15

0.0000

Volume:- -

Turnover:- -

Market Cap:211.75M

PE:25.37

High:9.15

Open:9.15

Low:9.15

Close:9.15

52wk High:9.30

52wk Low:7.16

Shares:23.14M

Float Shares:- -

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.3606

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

IN8bio presents Phase I/II data from INB-200 trials

TIPRANKS

·

Jan 12

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

GlobeNewswire

·

Oct 29, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INB"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INB\",,,,,undefined,":{"symbol":"INB","market":"US","secType":"STK","nameCN":"Cohen & Steers Global Income Builder Inc","latestPrice":9.15,"timestamp":1576875600000,"preClose":9.15,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":0,"shares":23142000,"eps":0.3606,"marketStatus":"Delisted","change":0,"latestTime":"12-20 16:00:00 EST","open":9.15,"high":9.15,"low":9.15,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.3606,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":9.15,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INB\",,,,,undefined,":{"symbol":"INB","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":23142000,"dividePrice":0,"high":9.15,"amplitude":0,"preClose":9.15,"low":9.15,"week52Low":7.1599,"pbRate":"--","week52High":9.3,"institutionHeld":0,"latestPrice":9.15,"eps":0.3606,"divideRate":0,"volume":0,"delay":0,"ttmEps":0.3606,"open":9.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-12-03","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-12-04","currency":"USD","type":"dividend","dateTimestamp":1575349200000},{"market":"US","date":"2019-11-12","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-11-13","currency":"USD","type":"dividend","dateTimestamp":1573534800000},{"market":"US","date":"2019-10-15","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-10-16","currency":"USD","type":"dividend","dateTimestamp":1571112000000},{"market":"US","date":"2019-09-17","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-09-18","currency":"USD","type":"dividend","dateTimestamp":1568692800000},{"market":"US","date":"2019-08-20","symbol":"INB","amount":0.062,"name":"Cohen & Steers Global Income Bui","payableDate":"2019-08-21","currency":"USD","type":"dividend","dateTimestamp":1566273600000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INB\",market:\"US\",,,undefined,":[{"executeDate":"2017-01-17","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"},{"executeDate":"2017-02-14","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"},{"executeDate":"2017-03-21","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":null,"paymentDate":null,"value":0.069,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"INB\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602752548","title":"IN8bio presents Phase I/II data from INB-200 trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2602752548","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602752548?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:35","pubTimestamp":1768224956,"startTime":"0","endTime":"0","summary":"IN8bio (INAB) reported updated clinical data from its INB-200 Phase 1 and INB-400 Phase 2 trials in newly diagnosed glioblastoma. The prior results...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/in8bio-presents-phase-i-ii-data-from-inb-200-trials-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/in8bio-presents-phase-i-ii-data-from-inb-200-trials-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","INB","BK4139","INAB"],"gpt_icon":0},{"id":"2579033789","title":"IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2579033789","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579033789?lang=en_us&edition=fundamental","pubTime":"2025-10-29 20:00","pubTimestamp":1761739200,"startTime":"0","endTime":"0","summary":"NEW YORK, Oct.  29, 2025  (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune disea","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/29/3176342/0/en/IN8bio-Expands-INB-100-Phase-1-Clinical-Trial-with-Addition-of-The-Ohio-State-University-as-New-Site.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","STT","LU1894683348.USD","INAB","BK4585","BK4588","BK4139","IE00B64PRP62.GBP","LU1883839398.USD","IE00B3QW5Z07.USD","INB","IE0034235188.USD","LU1894683264.USD","LU0061475181.USD","BK4539","IE00BGHQF748.EUR"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/INB\",params:#limit:6,delay:false,,,undefined,":[]}}